These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8859934)

  • 1. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure.
    Muntinga HJ; van der Vring JA; Niemeyer MG; van den Berg F; Knol HR; Bernink PJ; van der Wall EE; Blanksma PK; Lie KI
    J Cardiovasc Pharmacol; 1996 May; 27(5):652-6. PubMed ID: 8859934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
    Rousseau MF; Hayashida W; van Eyll C; Hess OM; Benedict CR; Ahn S; Chapelle F; Kobrin I; Pouleur H
    J Am Coll Cardiol; 1996 Oct; 28(4):972-9. PubMed ID: 8837576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
    Hassager C; Thygesen K; Grande P; Fischer Hansen J; Mickley H; Gustafsson I; Skagen K; Steensgaard-Hansen F
    Cardiology; 2001; 96(2):65-71. PubMed ID: 11740134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of calcium antagonists in a rat model of heart failure.
    Mulder P; Richard V; Thuillez C
    Cardiology; 1998; 89 Suppl 1():33-7. PubMed ID: 9570427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
    Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
    J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
    Sandmann S; Min JY; Meissner A; Unger T
    Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.
    Levine TB; Bernink PJ; Caspi A; Elkayam U; Geltman EM; Greenberg B; McKenna WJ; Ghali JK; Giles TD; Marmor A; Reisin LH; Ammon S; Lindberg E
    Circulation; 2000 Feb; 101(7):758-64. PubMed ID: 10683349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
    Palazzuoli A; Quatrini I; Vecchiato L; Scali C; De Paola V; Iovine F; Martini G; Nuti R
    Minerva Cardioangiol; 2005 Aug; 53(4):321-8. PubMed ID: 16177676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
    Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
    Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
    Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
    Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.
    Setaro JF; Zaret BL; Schulman DS; Black HR; Soufer R
    Am J Cardiol; 1990 Oct; 66(12):981-6. PubMed ID: 2220622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
    Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
    J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique cardioprotective action of the new calcium antagonist mibefradil.
    Schulz R; Post H; Jalowy A; Backenköhler U; Dörge H; Vahlhaus C; Heusch G
    Circulation; 1999 Jan; 99(2):305-11. PubMed ID: 9892599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
    Billman GE; Hamlin RL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.